Download PDF
Z Gastroenterol 2014; 52(12): 1485-1492
DOI: 10.1055/s-0034-1385562
Mitteilungen
© Georg Thieme Verlag KG Stuttgart · New York

Empfehlungen zur Anwendung der fäkalen Mikrobiotatransplantation „Stuhltransplantation“: Konsensus der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) in Zusammenarbeit mit der Österreichischen Gesellschaft für Infektiologie und Tropenmedizin (OEGIT)

Recommendations for the use of faecal microbiota transplantation „stool transplantation“: consensus of the Austrian Society of Gastroenterology and Hepatology (ÖGGH) in cooperation with the Austrian Society of Infectious Diseases and Tropical Medicine
P. K. Kump
1   Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Graz
,
R. Krause
2   Sektion Infektiologie und Tropenmedizin, Universitätsklinik für Innere Medizin, Medizinische Universität Graz
,
C. Steininger
3   Klinische Abteilung für Infektionen und Tropenmedizin, Medizinische Universität Wien
,
H. P. Gröchenig
4   Medizinische Abteilung, Krankenhaus der Barmherzigen Brüder, St. Veit an der Glan
,
A. Moschen
5   Universitätsklinik für Innere Medizin I, Medizinische Universität Innsbruck
,
C. Madl
6   4. Medizinische Abteilung mit Gastroenterologie, Hepatologie und Zentralendoskopie, Krankenanstalt Rudolfstiftung, Wien
,
G. Novacek
7   Abt. Gastroenterologie & Hepatologie, Univ.-Klinik Innere Medizin III, Wien
,
F. Allerberger
8   Österreichische Agentur für Gesundheit und Ernährungssicherheit, AGES, Wien
,
C. Högenauer
1   Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Graz
› Author Affiliations
Further Information

Publication History

17 June 2014

13 October 2014

Publication Date:
04 December 2014 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die intestinale Mikrobiota hat für die Erhaltung der Gesundheit des menschlichen Organismus eine zentrale Bedeutung und dient insbesondere auch der Abwehr von intestinalen Pathogenen. Veränderungen der intestinalen Mikrobiota, auch als Dysbiose bezeichnet, spielen eine entscheidende Rolle in der Pathogenese von vielen Erkrankungen. Als fäkale Mikrobiotatransplantation (FMT) oder Stuhltransplantation wird die Übertragung von Stuhlmikroorganismen eines gesunden Spenders in den Gastrointestinaltrakt eines erkrankten Patienten bezeichnet, um ein gestörtes Mikrobiom zu behandeln. Die Indikation zu dieser therapeutischen Intervention ist zumeist die rezidivierende Clostridium-difficile-Infektion (CDI). Mittlerweile gibt es bei dieser Indikation überzeugende Daten von einigen großen nicht kontrollierten Studien und einer kontrollierten randomisierten Studie sowie Beobachtungsstudien bei einer großen Anzahl an Patienten. Daher wird die FMT mittlerweile von internationalen Fachgesellschaften bei rezidivierender CDI mit hoher Evidenz empfohlen. Andere potenzielle Indikationen für die FMT sind die fulminante CDI und chronisch-entzündliche Darmerkrankungen. Bei der Anwendung der FMT bestehen vielen offene Fragen für die Praxis v. a. bez. Voruntersuchungen des Spenders, der Aufbereitung des Stuhl- sowie des Applikationswegs. Es sind unterschiedliche Applikationsformen beschrieben worden, wobei die Verabreichung der FMT in den unteren Gastrointestinaltrakt wegen weniger Nebenwirkungen gegenüber der Gaben in den oberen Gastrointestinaltrakt zu bevorzugen ist. Die vorliegenden Publikationen berichten nur über wenige schwere Nebenwirkungen der FMT. Trotzdem wird diese Therapieform derzeit v. a. wegen potenzieller Sicherheitsaspekte und Unklarheiten bez. des rechtlichen Status heftig in Fachkreisen diskutiert. Dieser Konsensusreport der Österreichischen Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH) in Kooperation mit der Österreichischen Gesellschaft für Infektionskrankheiten und Tropenmedizin dient daher Ärzten, die diese Methode benutzen, als eine Anleitung für deren Anwendung basierend auf Daten der rezenten medizinischen Literatur.

Abstract

The intestinal microbiota has a pivotal role in the maintenance of health of the human organism, especially in the defense against pathogenic microorganisms. Alterations in the microbiota, also termed dysbiosis, seem to be involved in the pathogenesis of a variety of intestinal and extraintestinal diseases. Fecal microbiota transplantation (FMT), also known as stool transplantation, is a therapeutic procedure aiming at restoring an altered intestinal microbiota by administration of stool microorganisms from a healthy donor into the intestinal tract of a patient. FMT is most commonly used for recurrent forms of Clostridium difficile infections (CDI). There are currently many cohort studies in a large number of patients and a randomized controlled trial showing a dramatic effect of FMT for this indication. Therefore FMT is recommended by international medical societies for the treatment of recurrent CDI with high scientific evidence. Other potential indications are the treatment of fulminant CDI or the treatment of inflammatory bowel diseases. In the practical utilization of FMT there are currently several open questions regarding the screening of stool donors, the processing of stool and the mode of FMT application. Different modes of FMT application have been described, the application into the colon has to be preferred due to less reported side effects than the application into the upper gastrointestinal tract. So far only very few side effects due to FMT have been reported, nevertheless the use and risks of FMT are currently intensely debated in the medical community. This consensus report of the Austrian society of gastroenterology and hepatology (ÖGGH) in cooperation with the Austrian society of infectious diseases and tropical medicine provides instructions for physicians who want to use FMT which are based on the current medical literature.

Schlüsselwörter

pseudomembranöse Kolitis - chronisch-entzündliche Darmerkrankung - infektiöse Kolitis

Key words

pseudomembranous colitis - chronic inflammatory bowel disease - infectious colitis
 

  • Literatur

  • 1 Lawley TD, Walker AW. Intestinal colonization resistance. Immunology 2013; 138: 1-11
    CrossrefPubMedGoogle Scholar
  • 2 Allerberger F. Time to act against Clostridium difficile infection. Clin Microbiol Infect 2012; 18 (Suppl. 06) 1
    PubMedGoogle Scholar
  • 3 Schmid D, Kuo HW, Simons E et al. All-cause mortality in hospitalized patients with infectious diarrhea: Clostridium difficile versus other enteric pathogens in Austria from 2008 to 2010. J Infect Public Health 2014; 7: 133-144
    CrossrefPubMedGoogle Scholar
  • 4 Högenauer C. Clostridium difficile Infektion – Prävention, Diagnose, Therapie. 2. Aufl.. Bremen: UNI-MED 2014: 48-68
    Google Scholar
  • 5 Mattila E, Uusitalo-Seppala R, Wuorela M et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142: 490-496
    CrossrefPubMedGoogle Scholar
  • 6 Song Y, Garg S, Girotra M et al. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLoS One 2013; 8: e81330
    CrossrefPubMedGoogle Scholar
  • 7 Kassam Z, Lee CH, Yuan Y et al. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-508
    CrossrefPubMedGoogle Scholar
  • 8 Borody TJ, Campbell J. Fecal microbiota transplantation: techniques, applications, and issues. Gastroenterol Clin North Am 2012; 41: 781-803
    CrossrefPubMedGoogle Scholar
  • 9 Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002
    CrossrefPubMedGoogle Scholar
  • 10 van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415
    CrossrefPubMedGoogle Scholar
  • 11 Cammarota G, Ianiro G, Gasbarrini A. Fecal Microbiota Transplantation for the Treatment of Clostridium difficile Infection: A Systematic Review. J Clin Gastroenterol 2014; 48: 693-702
    CrossrefPubMedGoogle Scholar
  • 12 Lee CH, Belanger JE, Kassam Z et al. The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis 2014; 33: 1425-1428
    CrossrefPubMedGoogle Scholar
  • 13 Brandt LJ. American Journal of Gastroenterology Lecture: Intestinal microbiota and the role of fecal microbiota transplant (FMT) in treatment of C. difficile infection. Am J Gastroenterol 2013; 108: 177-185
    CrossrefPubMedGoogle Scholar
  • 14 Kelly CR, Ihunnah C, Fischer M et al. Fecal Microbiota Transplant for Treatment of Clostridium difficile Infection in Immunocompromised Patients. Am J Gastroenterol 2014; 109: 1065-1071
    CrossrefPubMedGoogle Scholar
  • 15 Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014; 20 (Suppl. 02) 1-26
    PubMedGoogle Scholar
  • 16 Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-372
    CrossrefPubMedGoogle Scholar
  • 17 van der Wilden GM, Chang Y, Cropano C et al. Fulminant Clostridium difficile colitis: prospective development of a risk scoring system. J Trauma Acute Care Surg 2014; 76: 424-430
    CrossrefPubMedGoogle Scholar
  • 18 Butt E, Foster JA, Keedwell E et al. Derivation and validation of a simple, accurate and robust prediction rule for risk of mortality in patients with Clostridium difficile infection. BMC Infect Dis 2013; 13: 316
    CrossrefPubMedGoogle Scholar
  • 19 Bhangu A, Nepogodiev D, Gupta A et al. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99: 1501-1513
    CrossrefPubMedGoogle Scholar
  • 20 Lamontagne F, Labbe AC, Haeck O et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245: 267-272
    CrossrefPubMedGoogle Scholar
  • 21 Neemann K, Eichele DD, Smith PW et al. Fecal microbiota transplantation for fulminant Clostridium difficile infection in an allogeneic stem cell transplant patient. Transpl Infect Dis 2012; 14: E161-E165
    CrossrefPubMedGoogle Scholar
  • 22 Trubiano JA, Gardiner B, Kwong JC et al. Faecal microbiota transplantation for severe clostridium difficile infection in the intensive care unit. Eur J Gastroenterol Hepatol 2013; 25: 255-257
    CrossrefPubMedGoogle Scholar
  • 23 Bauchinger S, Hoffmann KM, Hauer AC et al. Einsatz der fäkalen Mikrobiotatransplantation (Stuhltransplantation) bei fulminanter Clostridium-difficile-Pankolitis und CF. Monatsschrift Kinderheilkunde 2013; 161: 51
    PubMedGoogle Scholar
  • 24 Vrieze A, Van Nood E, Holleman F et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916
    CrossrefPubMedGoogle Scholar
  • 25 de Vrieze J. Medical research. The promise of poop. Science 2013; 341: 954-957
    CrossrefPubMedGoogle Scholar
  • 26 Borody TJ, Warren EF, Leis SM et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004; 38: 475-483
    CrossrefPubMedGoogle Scholar
  • 27 Borody TJ, Warren EF, Leis S et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42-47
    CrossrefPubMedGoogle Scholar
  • 28 Borody TJ, George L, Andrews P et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?. Med J Aust 1989; 150: 604
    PubMedGoogle Scholar
  • 29 Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1: 164
    PubMedGoogle Scholar
  • 30 Kump PK, Grochenig HP, Lackner S et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Inflamm Bowel Dis 2013; 19: 2155-2165
    CrossrefPubMedGoogle Scholar
  • 31 Angelberger S, Reinisch W, Makristathis A et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol 2013; 108: 1620-1630
    CrossrefPubMedGoogle Scholar
  • 32 Kump PK, Gröchenig HP, Spindelböck W et al. Preliminary clinical results of repeatedly fecal microbiota transplantation (FMT) in chronic active ulcerative colitis UEG Journal. 2013; 1 (Suppl. 01) A57
    PubMedGoogle Scholar
  • 33 Borody TJ, Wettstein A, Nowak A et al. Fecal microbiotra transplantation (FMT) eradicates Clostridium difficile infection (CDI) in inflammatory bowel disease (IBD). UEG Journal 2013; 1 (Suppl. 01) A57
    PubMedGoogle Scholar
  • 34 Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther 2012; 36: 503-516
    CrossrefPubMedGoogle Scholar
  • 35 Turnbaugh PJ, Hamady M, Yatsunenko T et al. A core gut microbiome in obese and lean twins. Nature 2009; 457: 480-484
    Google Scholar
  • 36 Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc 2013; 78: 240-249
    CrossrefPubMedGoogle Scholar
  • 37 Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012; 46: 145
    CrossrefPubMedGoogle Scholar
  • 38 Owens C, Broussard E, Surawicz C. Fecal microbiota transplantation and donor standardization. Trends Microbiol 2013; 21: 443-445
    CrossrefPubMedGoogle Scholar
  • 39 Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbiota transplantation for treatment of Clostridium difficile infection despite asymptomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108: 1367
    PubMedGoogle Scholar
  • 40 Hamilton MJ, Weingarden AR, Sadowsky MJ et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012; 107: 761-767
    CrossrefPubMedGoogle Scholar
  • 41 Youngster I, Sauk J, Pindar C et al. Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study. Clin Infect Dis 2014; 58: 1515-1522
    CrossrefPubMedGoogle Scholar
  • 42 Hamilton MJ, Weingarden AR, Unno T et al. High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut microbes 2013; 4: 125-135
    CrossrefPubMedGoogle Scholar
  • 43 Gorkiewicz G, Thallinger GG, Trajanoski S et al. Alterations in the colonic microbiota in response to osmotic diarrhea. PLoS One 2013; 8: e55817
    CrossrefPubMedGoogle Scholar
  • 44 Bakken JS, Borody T, Brandt LJ et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-1049
    CrossrefPubMedGoogle Scholar
  • 45 Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580-585
    CrossrefPubMedGoogle Scholar
  • 46 Solari PR, Fairchild PG, Noa LJ et al. Tempered enthusiasm for Fecal transplantation. Clin Infect Dis 2014; 59: 319-320
    PubMedGoogle Scholar
  • 47 Friedman-Moraco RJ, Mehta AK, Lyon GM et al. Fecal microbiota transplantation for refractory Clostridium difficile colitis in solid organ transplant recipients. Am J Transplant 2014; 14: 477-480
    CrossrefPubMedGoogle Scholar